nature portfolio

Corresponding author(s):	CJ Rijpkema
Last updated by author(s):	Feb 17, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_				
C -	トつ	+1	ct.	ics
	п		``	11 >

n/a	Confirmed				
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
\boxtimes	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
	The statis	tical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section.			
	A descript	tion of all covariates tested			
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
\boxtimes	Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated				
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software and code					
Policy information about <u>availability of computer code</u>					
Da	ata collection	NA			
Da	nta analysis	NA			
		g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.			

Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data underlying this article (both for the three general practice registration networks and Nivel-PCD) will be shared at reasonable request to the corresponding author. For Nivel-PCD this follows the governance of the 'Nivel Primary Care Database'. Data in the 'Nivel Primary Care Database' are extracted from the electronic health records of OOH services. The use of the data for research purposes is subject to approval by a committee representing the health professionals who

recorded the data in their electronic health records, reviewing proposals on the relevance for, and privacy of, the OOH services and their patients. (https:// www.nivel.nl/en/nivel-zorgregistraties-eerste-lijn/nivel-primary-care-database).

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender

The findings did not only apply to one sex. We used the sex variable from the general practice registry and out-of-hours services registry. We did not report on an individual level. In Table 2 we have given a descriptive representation of how many patients are male and female in the study population (in percentage).

Population characteristics

The population characteristics are displayed in Table 2.

Recruitment

In our observational study, deidentified, routinely recorded, electronic health records data from general practices and out-ofhours services were used. For general practices (during office hours), data from three electronic health records-based repositories in the Netherlands were used: 1) Academic General Practitioner Development Network (Academische Huisartsen Ontwikkel Netwerk - AHON) with 57 participating practices, 2) Family Medicine Network (FaMe-Net) with 6 participating practices, and 3) Research Network Family Medicine Maastricht (RNFM) with 27 participating practices. For the OOH services, data from Nivel Primary Care Database (Nivel-PCD) were used, representing a joint catchment area of almost 12 million people from the Netherlands (60% of all OOH services, and 70% of the Dutch population).

Ethics oversight

X Life sciences

Ethical approval for this study was waived by the medical ethics committee of the University Medical Centre Groningen (reference number: 2020/309). For Nivel-PCD, the project has been approved by the relevant governance bodies of Nivel-PCD under no. NZR-00320.087.

Ecological, evolutionary & environmental sciences

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for	your research. If you are not sure,	, read the appropriate sections b	efore making your selection.

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Behavioural & social sciences

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

No sample-size calculations were performed, because our databases consists of a sufficient number of patients (i.e. 420.000 patients for Sample size general practices and 70% of the Dutch population for out-of-hours services)

Data exclusions

The data specialists prepared the data based on quality criteria and excluded general practices/out-of-hours services when they do not meet the criteria. Researchers excluded contacts who were not for asthma or COPD.

Replication When (other) researchers have access to the data, analyses can be reproduced.

Randomization Not relevant to our study

Blinding Blinding was not relevent to our study

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

		٦
	Ē	١,
	È	4
	C	Ξ
	Ę	3
	C	D
	τ	7
	7	≺
	٤	ユ
	≤	7
	7	≺
	2	<u> </u>
	7	₹
	(ر
	Ζ	ヹ
ı	<u>c</u>	브
	ζ	ر
	C	D
	Ξ	ב
	Ξ	≟
	Ę	כ
	<u> </u>	⊇
	í.	n
	č	ä
	È	₹
	Ē	ರ
		5
	Ξ	ゴ
	Ē	ע
Ϊ,	_	Ż
	7	`

	Ċ	,	
i			
			L
	c		5
		Ş	

Materials & experimental systems		Methods		
n/a	Involved in the study	n/a	Involved in the study	
\boxtimes	Antibodies	\boxtimes	ChIP-seq	
\boxtimes	Eukaryotic cell lines	\boxtimes	Flow cytometry	
\boxtimes	Palaeontology and archaeology	\boxtimes	MRI-based neuroimaging	
\boxtimes	Animals and other organisms	'		
\boxtimes	Clinical data			
\boxtimes	Dual use research of concern			